FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2059970814> ?p ?o ?g. }

• W2059970814 endingPage "257" @default.
• W2059970814 startingPage "257" @default.
• W2059970814 abstract "Early stage and long term treatment of multiple sclerosis with interferon-β Angela Applebee, Hillel PanitchDepartment of Neurology, University of Vermont College of Medicine, and Neurology Service, Fletcher Allen Health Care, Burlington, VT, USAAbstract: Multiple sclerosis (MS) affects young adults during the most productive years of their lives, and until recently many neurologists were limited to treating symptoms and attacks without any ability to alter the disease course. The 1990s ushered in an era of possibility with the approval of three interferon-beta (IFNβ) therapies for the treatment of MS. Though the mechanism of action of these agents is not completely understood, it is clear they reduce magnetic resonance imaging (MRI) activity as well as improve clinical outcomes. The principal randomized, blinded, multicenter trials of IFNβ all point to the need for early treatment soon after the diagnosis of MS is made. Efficacy has also been shown in patients treated after a first demyelinating event. Data on IFNβ in the treatment of secondary progressive MS (SPMS) is not impressive, although it shows some benefit in SPMS patients who continue to experience MRI activity and clinical relapses, signifying a continued inflammatory component to their disease. There has been no proven efficacy of IFNβ in the treatment of primary progressive MS (PPMS). The IFNβ therapies are generally well tolerated with a favorable side effect profile. Despite benefits in MRI and clinical measures such as relapse rates and Expanded Disability Status Scale progression, patients continue to exhibit clinical progression and radiological atrophy, pointing to confounding factors and perhaps multiple etiologies of a disease that is not yet fully understood. In addition, the subject of neutralizing antibodies has recently assumed importance. The significance of these on treatment efficacy is uncertain, and until a universally accepted reliable assay is adopted, the decision to change treatment continues to rely on the clinical interpretation of the patient’s history and physical examination. Additional recommendations for management of patients, informed by the best available evidence, are also presented. Keywords: interferon-β, multiple sclerosis, clinical trials, neutralizing antibodies" @default.
• W2059970814 created "2016-06-24" @default.
• W2059970814 creator A5056460527 @default.
• W2059970814 creator A5081807013 @default.
• W2059970814 date "2009-05-01" @default.
• W2059970814 modified "2023-10-16" @default.
• W2059970814 title "Early stage and long term treatment of multiple sclerosis with interferon-β" @default.
• W2059970814 cites W1487241851 @default.
• W2059970814 cites W1936917066 @default.
• W2059970814 cites W1968168664 @default.
• W2059970814 cites W1968295744 @default.
• W2059970814 cites W1973256647 @default.
• W2059970814 cites W1977759475 @default.
• W2059970814 cites W1978243650 @default.
• W2059970814 cites W1980647798 @default.
• W2059970814 cites W1982113768 @default.
• W2059970814 cites W1983999022 @default.
• W2059970814 cites W1997824576 @default.
• W2059970814 cites W2000599573 @default.
• W2059970814 cites W2007156951 @default.
• W2059970814 cites W2008336429 @default.
• W2059970814 cites W2008369480 @default.
• W2059970814 cites W2020530458 @default.
• W2059970814 cites W2024061399 @default.
• W2059970814 cites W2034432056 @default.
• W2059970814 cites W2035167238 @default.
• W2059970814 cites W2036284753 @default.
• W2059970814 cites W2038316210 @default.
• W2059970814 cites W2038428996 @default.
• W2059970814 cites W2040609547 @default.
• W2059970814 cites W2041686092 @default.
• W2059970814 cites W2044173905 @default.
• W2059970814 cites W2044566162 @default.
• W2059970814 cites W2054010811 @default.
• W2059970814 cites W2056736742 @default.
• W2059970814 cites W2061005334 @default.
• W2059970814 cites W2064611810 @default.
• W2059970814 cites W2069947868 @default.
• W2059970814 cites W2076814339 @default.
• W2059970814 cites W2078580553 @default.
• W2059970814 cites W2085317592 @default.
• W2059970814 cites W2085394455 @default.
• W2059970814 cites W2087589796 @default.
• W2059970814 cites W2087939913 @default.
• W2059970814 cites W2092276202 @default.
• W2059970814 cites W2093471482 @default.
• W2059970814 cites W2095666175 @default.
• W2059970814 cites W2097659800 @default.
• W2059970814 cites W2097669496 @default.
• W2059970814 cites W2105477343 @default.
• W2059970814 cites W2105490558 @default.
• W2059970814 cites W2111468824 @default.
• W2059970814 cites W2112165124 @default.
• W2059970814 cites W2112246282 @default.
• W2059970814 cites W2114225021 @default.
• W2059970814 cites W2117751925 @default.
• W2059970814 cites W2118014174 @default.
• W2059970814 cites W2120389810 @default.
• W2059970814 cites W2123129990 @default.
• W2059970814 cites W2123226439 @default.
• W2059970814 cites W2130355701 @default.
• W2059970814 cites W2135900660 @default.
• W2059970814 cites W2139367012 @default.
• W2059970814 cites W2142472522 @default.
• W2059970814 cites W2146802292 @default.
• W2059970814 cites W2148814846 @default.
• W2059970814 cites W2150155868 @default.
• W2059970814 cites W2150378783 @default.
• W2059970814 cites W2151041276 @default.
• W2059970814 cites W2154716846 @default.
• W2059970814 cites W2156111518 @default.
• W2059970814 cites W2158488354 @default.
• W2059970814 cites W2159963451 @default.
• W2059970814 cites W2165547142 @default.
• W2059970814 cites W2168301183 @default.
• W2059970814 cites W2169098250 @default.
• W2059970814 cites W2312240793 @default.
• W2059970814 cites W2313649737 @default.
• W2059970814 cites W2411398998 @default.
• W2059970814 cites W2513768836 @default.
• W2059970814 cites W2574627421 @default.
• W2059970814 cites W2944877505 @default.
• W2059970814 cites W24687004 @default.
• W2059970814 doi "https://doi.org/10.2147/btt.s1473" @default.
• W2059970814 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2726076" @default.
• W2059970814 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19707414" @default.
• W2059970814 hasPublicationYear "2009" @default.
• W2059970814 type Work @default.
• W2059970814 sameAs 2059970814 @default.
• W2059970814 citedByCount "6" @default.
• W2059970814 countsByYear W20599708142012 @default.
• W2059970814 countsByYear W20599708142015 @default.
• W2059970814 countsByYear W20599708142016 @default.
• W2059970814 countsByYear W20599708142017 @default.
• W2059970814 countsByYear W20599708142018 @default.
• W2059970814 crossrefType "journal-article" @default.
• W2059970814 hasAuthorship W2059970814A5056460527 @default.
• W2059970814 hasAuthorship W2059970814A5081807013 @default.

• next